Houston, TX – November 21, 2023 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023, and will participate in one-on-one meetings with investors throughout the day, in New York, NY.
Presentation Details:
Date: Tuesday, November 28, 2023
Time: 10:10 a.m.-10:30 a.m. EST
Location: Lotte New York Palace, 455 Madison Ave, New York, NY 10022
About Tvardi Therapeutics:
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company has now initiated three Phase 2 clinical programs in hepatocellular carcinoma (NCT05440708), metastatic breast cancer (NCT05384119), and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit the website for Tvardi Therapeutics.
Contact:
Tvardi Investor Relations
Sara Manning
ir@tvardi.com